Research To Practice | Oncology Videos podcast

Player FM - Internet Radio Done Right

47 subscribers

Menambahkan eight tahun yang lalu

Konten disediakan oleh Dr Neil Love. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Dr Neil Love atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

Tinfoil Swans

1
Antoni Porowski and the Right Time to Leave a Party 46:55

13 hari yang lalu46:55

Putar Nanti

Daftar

Suka

Menyukai

46:55

"Queer Eye" and "No Taste Like Home" star Antoni Porowski joins Tinfoil Swans live at the Food & Wine Classic in Aspen for a heartfelt and humorous conversation about identity, vulnerability, and finding meaning through food. He opens up about his path from actor and caterer to TV host and storyteller, the emotional layers of cooking, navigating fame, and the gentle art of knowing when to leave the party. Along the way, he shares reflections on therapy, self-care, family dynamics — and what turning 40 taught him. Sponsor: Old Fitzgerald® Kentucky Straight Bourbon Whiskey. Bardstown, KY. 50% Alc./Vol. Think Wisely. Drink Wisely. Learn more about your ad choices. Visit podcastchoices.com/adchoices…

Research To Practice | Oncology Videos

Beranda serial•Feed

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

821 episode

#Science #Medicine #Cancer #Neillove #Oncology #Researchtopractice #Fitness #Dr Neil Love #Video

Research To Practice | Oncology Videos

47 subscribers

updated 3 hari yang lalu

Beranda serial•Feed

821 episode

#Science #Medicine #Cancer #Neillove #Oncology #Researchtopractice #Fitness #Dr Neil Love #Video

Semua episode

Research To Practice | Oncology Videos

1
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 17:45

3 hari yang lalu17:45

17:45

Featuring an interview with Dr Jacob Sands, including the following topics: TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00) Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52) Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025; Abstract 8599 . Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024; Abstract LBA8500 . Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26) Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024; Abstract PL02.11 . CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma | Oncology Q&A for Patients: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma 1:02:11

3 hari yang lalu1:02:11

1:02:11

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: Introduction: Multiple Myeloma — 2005 to 2025 (0:00) Questions from the Beginning (7:53) Choosing Options (13:54) Clinical Trials (18:03) Neuropathy (23:55) Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40) Bispecific Antibodies (35:18) Antibody-Drug Conjugates (43:08) Interacting with the Oncology Team (51:47) Other Questions (57:30) Educational and presenter information…

Research To Practice | Oncology Videos

1
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations 43:02

6 hari yang lalu43:02

43:02

Featuring an interview with Dr Jorge Cortes, including the following topics: Overview of common molecular profiles in newly diagnosed acute myeloid leukemia (AML) (0:00) Clinical presentation of AML with a FLT3 mutation; implications of clinical data from the Phase III RATIFY trial of the FLT3 inhibitor midostaurin (5:38) Potential incorporation of a FLT3 inhibitor with azacitidine/venetoclax for transplant-ineligible patients with FLT3-mutant AML (10:32) Clinical benefit with quizartinib for patients with FLT3-like genetic profile; selection of FLT3 inhibitor as a component of initial therapy for individuals with AML with a FLT3-ITD mutation (14:04) Overview of FDA-approved IDH inhibitors enasidenib, ivosidenib and olutasidenib; differentiation syndrome as a class effect of IDH inhibitors in AML (20:31) Case: A woman in her late 60s with newly diagnosed AML with FLT3-ITD and NPM1 mutations receives 7+3 chemotherapy in combination with quizartinib (31:07) Case: A patient in their late 70s with multiple comorbidities and newly diagnosed IDH1-mutant AML (37:53) CME information and select publications…

Research To Practice | Oncology Videos

1
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations (Companion Faculty Lecture) 34:08

7 hari yang lalu34:08

34:08

Featuring a slide presentation and related discussion from Dr Jorge Cortes, including the following topics: Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia — Dr Cortes (0:00) CME information and select publications

Research To Practice | Oncology Videos

1
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 59:03

10 hari yang lalu59:03

59:03

Featuring perspectives from Dr Benjamin Levy, including the following topics: Introduction: The Boards (0:00) Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43) Immunotherapy for Metastatic NSCLC (24:41) Antibody-Drug Conjugates (33:46) Novel Bispecific Antibodies (42:08) Journal Club with Dr Levy (51:28) CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma — Optimizing the Selection of First-Line Therapy 57:12

11 hari yang lalu57:12

57:12

Featuring perspectives from Prof Xavier Leleu and Dr Peter Voorhees, including the following topics: Introduction: Myeloma Time Capsule (0:00) Smoldering Myeloma (7:21) Autologous Stem Cell Transplant (ASCT) Eligible Patients (13:05) ASCT Ineligible Patients (32:18) Subcutaneous Anti-CD38 Antibodies (47:24) Special Considerations (54:27) CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma | Peter Voorhees, MD 1:00:09

12 hari yang lalu1:00:09

1:00:09

Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma | Faculty Presentation — Peter Voorhees, MD CME information and select publications

Research To Practice | Oncology Videos

1
Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 20:18

15 hari yang lalu20:18

20:18

Featuring an interview with Dr Erika Hamilton, including the following topics: Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00) Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025; Abstract VP1-2025 . First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02) Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025; Abstract LBA109 . Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06) Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53) Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025; Abstract 1019 . Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024; Abstract 104 . Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024; Abstract LBA1004 . CME information and select publications…

Research To Practice | Oncology Videos

1
Gynecologic Cancers — Year in Review Series on Relevant New Datasets and Advances 59:34

16 hari yang lalu59:34

59:34

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics: Introduction: Tale of Two Cities — ASCO 2025 (0:00) Ovarian Cancer (11:20) HER2-Positive Gynecologic Cancers (31:28) Endometrial Cancer (40:16) Cervical Cancer (51:14) CME information and select publications…

Research To Practice | Oncology Videos

1
Endometrial and Cervical Cancer | Susana Banerjee, MBBS, MA, PhD 28:13

17 hari yang lalu28:13

28:13

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD CME information and select publications

Research To Practice | Oncology Videos

1
Ovarian Cancer | Ursula Matulonis, MD 36:24

18 hari yang lalu36:24

36:24

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 1: Ovarian Cancer — Ursula Matulonis, MD CME information and select publications

Research To Practice | Oncology Videos

1
Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient Care 44:12

19 hari yang lalu44:12

44:12

Featuring an interview with Ms Kathleen D Burns, including the following topics: Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who received an androgen receptor inhibitor in combination with androgen deprivation therapy (0:00) Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) who received olaparib in combination with abiraterone (23:20) Case: A man in his mid 70s with mCRPC who received lutetium Lu 177 vipivotide tetraxetan (33:44) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management 27:45

20 hari yang lalu27:45

27:45

Featuring an interview with Dr Hope S Rugo, including the following topics: Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00) Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03) Management of common toxicities with approved ADCs (10:48) Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17) Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09) CME information and select publications…

Research To Practice | Oncology Videos

1
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management (Companion Faculty Lecture) 39:01

21 hari yang lalu39:01

39:01

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications…

Research To Practice | Oncology Videos

1
Soft Tissue Sarcoma and Other Connective Tissue Neoplasms — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 1:00:57

25 hari yang lalu1:00:57

1:00:57

Featuring perspectives from Dr Rashmi Chugh and Dr Mrinal Gounder, including the following topics: Introduction: Current Role of General Medical Oncologists in the Treatment of Soft Tissue Sarcomas (STS) (0:00) Incorporation of Novel Agents and Strategies into the Management of STS — Faculty Presentation (6:38) Incorporation of Novel Agents and Strategies into the Management of STS — Survey Questions (20:34) Evolving Treatment Paradigm for Locally Aggressive STS — Faculty Presentation (31:09) Evolving Treatment Paradigm for Locally Aggressive STS — Survey Questions (46:44) CME information and select publications…

Research To Practice | Oncology Videos

1
Renal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 58:54

26 hari yang lalu58:54

58:54

Featuring perspectives from Prof Laurence Albiges and Dr Tian Zhang, including the following topics: Introduction: Adjuvant Immunotherapy for Localized Renal Cell Carcinoma (RCC) (0:00) Metastatic Clear Cell RCC — Faculty Presentation (9:22) Metastatic Clear Cell RCC — Survey Questions (20:24) Non-Clear Cell RCC — Faculty Presentation (36:02) Non-Clear Cell RCC — Survey Questions (45:46) ASCO 2025 (50:12) CME information and select publications…

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 1:00:43

28 hari yang lalu1:00:43

1:00:43

Featuring perspectives from Dr Catherine C Coombs and Dr William G Wierda, including the following topics: Introduction (0:00) Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (19:25) First-Line Therapy for CLL — Dr Coombs (44:18) Novel Agents and Strategies for R/R CLL — Dr Wierda (57:27) CME information and select publications…

Research To Practice | Oncology Videos

1
Oncology Nursing Update: Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New Approaches 53:52

4 weeks yang lalu53:52

53:52

Featuring an interview with Ms Jennifer Filipi, including the following topics: Responsibilities of an oncology nurse and perspectives on the career (0:00) Case: A woman in her late 70s with BRCA1-mutated ovarian cancer (OC) (3:50) Case: A woman in her mid 40s, a mother of 3, with advanced OC (27:23) Case: A woman in her early 70s, a social worker, with platinum-refractory OC (40:02) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 58:41

5 weeks yang lalu58:41

58:41

Featuring perspectives from Dr Ajay K Nooka and Dr Paul G Richardson, including the following topics: Introduction: ASCO 2025 Showstoppers (0:00) Up-Front Treatment of Multiple Myeloma (MM) — Survey Questions (5:50) Emerging Novel Therapies for Relapsed/Refractory (R/R) MM — Faculty Presentation (11:57) Emerging Novel Therapies for R/R MM — Survey Questions (26:19) Current Management of R/R MM — Faculty Presentation (38:34) Current Management of R/R MM — Survey Questions (49:20) CME information and select publications…

Research To Practice | Oncology Videos

1
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates 1:28:42

5 weeks yang lalu1:28:42

1:28:42

Featuring perspectives from Prof Marina Chiara Garassino, Dr John V Heymach, Prof Solange Peters and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters (2:07) Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino (26:30) Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands (50:19) Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach (1:12:36) CME information and select publications…

Research To Practice | Oncology Videos

1
HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:28:55

5 weeks yang lalu1:28:55

1:28:55

Featuring perspectives from Dr Haley Ellis, Dr Sara Lonardi and Dr Kanwal Raghav, moderated by Dr Christopher Lieu, including the following topics: Introduction (0:00) Gastroesophageal Cancers — Dr Lonardi (1:54) Biliary Tract Cancers — Dr Ellis (39:20) Colorectal Cancer — Dr Raghav (1:07:10) CME information and select publications…

Research To Practice | Oncology Videos

1
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress 1:31:26

5 weeks yang lalu1:31:26

1:31:26

Featuring perspectives from Dr Jacqueline Broadway-Duren, Dr Bita Fakhri, Ms Corinne Hoffman and Dr Jeff Sharman, including the following topics: Introduction: Key Factors in the Management of Chronic Lymphocytic Leukemia (CLL) (0:00) Role of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors for Newly Diagnosed CLL (12:02) Role of Time-Limited Up-Front Treatment, Including Therapy Combining BTK Inhibitors and Venetoclax, for Newly Diagnosed CLL (37:55) Role of Pirtobrutinib for Relapsed/Refractory (R/R) CLL (1:02:07) CAR (Chimeric Antigen Receptor) T-Cell Therapy for R/R CLL (1:16:48) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Urothelial Bladder Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:00:12

6 weeks yang lalu1:00:12

1:00:12

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Prof Thomas Powles, moderated by Dr Galsky, including the following topics: Introduction (0:00) Current and Future Management of Muscle-Invasive Bladder Cancer — Prof Powles (1:14) Novel Intravesical Therapies Under Evaluation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (24:48) Selection and Sequencing of Therapy for Metastatic UBC — Dr Galsky (44:52) CME information and select publications…

Research To Practice | Oncology Videos

1
Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:59:43

6 weeks yang lalu1:59:43

1:59:43

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24) Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53) Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51) Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22) Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55) CME information and select publications…

Research To Practice | Oncology Videos

1
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:29:31

6 weeks yang lalu1:29:31

1:29:31

Featuring perspectives from Dr Anne Chiang, Ms Elizabeth Krueger, Ms Beth Sandy and Dr Erin Schenk, including the following topics: Introduction: Overview of Bispecific Antibodies (0:00) Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management (13:37) Case: 63-year-old man — Ms Krueger (23:36) Current Role of Tarlatamab in Therapy for SCLC (33:40) Case: 70-year-old woman — Ms Sandy (43:41) Future Directions in the Management of SCLC (50:45) Case: 81-year-old man — Ms Krueger (1:01:24) Unique Considerations in SCLC Management (1:09:29) Case: 67-year-old woman — Ms Sandy (1:22:53) NCPD information and select publications…

Research To Practice | Oncology Videos

1
For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress 1:29:40

6 weeks yang lalu1:29:40

1:29:40

Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics: Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00) Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09) First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03) Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31) Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:57:47

7 weeks yang lalu1:57:47

1:57:47

Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo, including the following topics: Introduction (0:00) Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52) Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10) Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09) Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O’Shaughnessy (1:04:00) Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51) CME information and select publications…

Research To Practice | Oncology Videos

1
Colorectal Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 2:02:11

7 weeks yang lalu2:02:11

2:02:11

Featuring perspectives from Dr Andrea Cercek, Dr Arvind Dasari, Dr J Randolph Hecht, Dr Pashtoon Kasi and Prof Eric Van Cutsem, moderated by Dr Hecht, including the following topics: Introduction (0:00) Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer (CRC) — Dr Dasari (2:20) Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC — Dr Cercek (28:32) Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease — Dr Kasi (54:07) Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC) — Dr Hecht (1:14:34) Identification and Care of Patients with mCRC and Actionable Genomic Alterations — Prof Van Cutsem (1:38:17) CME information and select publications…

Research To Practice | Oncology Videos

1
Ovarian and Endometrial Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:59:45

7 weeks yang lalu1:59:45

1:59:45

Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley, Dr Ritu Salani, Dr Alessandro D Santin and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:00) Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr O’Malley (27:23) Role of HER2-Targeted Therapy in Advanced OC, Endometrial Cancer (EC) and Other Gynecologic Cancers — Dr Santin (50:22) First-Line Therapy for Advanced EC — Dr Westin (1:15:00) Current Therapeutic Options for R/R EC; Novel Investigational Strategies for Newly Diagnosed and Recurrent Disease — Dr Salani (1:36:45) CME information and select publications…

Research To Practice | Oncology Videos

1
For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress 1:29:00

7 weeks yang lalu1:29:00

1:29:00

Featuring perspectives from Ms Ilene Galinsky, Dr Michael J Mauro, Dr Neil P Shah and Dr Sara M Tinsley-Vance, including the following topics: Introduction: Chronic Myeloid Leukemia (CML) as a Model for Targeted Treatment (0:00) Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML (12:37) Role of Asciminib for Newly Diagnosed CP-CML (47:46) Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment (1:14:06) Management of CP-CML After Failure of Initial Therapy (1:23:04) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Prostate Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:56:26

8 weeks yang lalu1:56:26

1:56:26

Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12) Current Treatment for Metastatic HSPC — Dr Armstrong (26:12) Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31) Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51) Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11) CME information and select publications…

Research To Practice | Oncology Videos

1
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies 54:07

8 weeks yang lalu54:07

54:07

Featuring an interview with Dr Patrick Y Wen, including the following topics: Glioma classification (0:00) Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50) Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55) Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46) Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30) Current and emergent strategies for the management of glioblastoma (31:27) Optimizing patient care and quality of life (46:24) CME information and select publications…

Research To Practice | Oncology Videos

1
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies (Companion Faculty Lecture) 28:39

8 weeks yang lalu28:39

28:39

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics: Classification and pathologic diagnosis of gliomas (0:00) Role of IDH inhibitors in the management of low-grade gliomas (6:37) Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53) CME information and select publications…

Research To Practice | Oncology Videos

1
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:57:52

8 weeks yang lalu1:57:52

1:57:52

Featuring perspectives from Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi A Jänne, Dr Suresh S Ramalingam, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics: Introduction (0:00) Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu (1:47) EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari (23:48) Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam (45:16) Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman (1:03:56) Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard (1:24:40) Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne (1:43:46) CME information and select publications…

Research To Practice | Oncology Videos

1
Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases 1:01:04

9 weeks yang lalu1:01:04

1:01:04

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics: Introduction: ASCO Preview (0:00) HER2-Positive Gastroesophageal Cancers (19:03) Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11) Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04) CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30) CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances 59:09

9 weeks yang lalu59:09

59:09

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics: Introduction: ASCO 2025 Preview (0:00) Anti-CD38 Antibodies (10:12) Belantamab Mafodotin (29:45) CAR T-Cell Therapy (40:57) Bispecific Antibodies (47:33) Other Novel Agents (56:46) CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma | Meletios-Athanasios (Thanos) C Dimopoulos, MD 27:33

9 weeks yang lalu27:33

27:33

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) — Meletios-Athanasios (Thanos) C Dimopoulos, MD CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma | Robert Z Orlowski, MD, PhD 27:53

9 weeks yang lalu27:53

27:53

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Robert Z Orlowski, MD, PhD CME information and select publications

Research To Practice | Oncology Videos

1
For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress 1:59:40

9 weeks yang lalu1:59:40

1:59:40

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances 59:19

9 weeks yang lalu59:19

59:19

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications…

Research To Practice | Oncology Videos

1
Myelofibrosis | John Mascarenhas, MD 32:33

10 weeks yang lalu32:33

32:33

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD CME information and select publications

Research To Practice | Oncology Videos

1
Myelofibrosis | Professor Claire Harrison 46:48

10 weeks yang lalu46:48

46:48

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison CME information and select publications

Research To Practice | Oncology Videos

1
For Oncology Nurses: Gastroesophageal Cancer — Proceedings from the 2025 Annual ONS Congress 1:32:42

10 weeks yang lalu1:32:42

1:32:42

Featuring perspectives from Dr Sunnie Kim, Ms Brooke Parker, Ms Michal Segal and Dr Manish Shah, including the following topics: Introduction: Clinical Presentation of Gastroesophageal Cancer (0:00) Management of Localized or Locally Advanced Gastroesophageal Cancers; Current and Future Role of Immune Checkpoint Inhibitors (21:44) Incorporation of Immunotherapeutic Strategies for HER2-Negative Metastatic Gastroesophageal Tumors (39:32) Role of Therapy Targeting CLDN18.2 in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (1:00:50) Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers (1:22:41) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances 58:22

10 weeks yang lalu58:22

58:22

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications…

Research To Practice | Oncology Videos

1
Non-Small Cell Lung Cancer | Joel W Neal, MD, PhD 30:11

10 weeks yang lalu30:11

30:11

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting HER2, MET, BRAF and KRAS G12C — Joel W Neal, MD, PhD CME information and select publications…

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.